CONDUIT™ Interbody Platform composed of the EIT (Emerging Implant Technologies) Cellular Titanium® ( DrugBank: Titanium )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 70 | Spinal stenosis | 1 |
70. Spinal stenosis
Clinical trials : 96 / Drugs : 203 - (DrugBank : 60) / Drug target genes : 66 - Drug target pathways : 89
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05023733 (ClinicalTrials.gov) | October 1, 2021 | 16/8/2021 | Clinical and Radiographic Outcomes of TLIF w/3D Printed Cellular Implant | Clinical and Radiographic Outcomes of Transforaminal Lumbar Interbody Fusion (TLIF) With a Novel 3D Printed Cellular Titanium Implant | Foraminal Stenosis;Degenerative Disc Disease;Lumbar Spondylolisthesis;Lumbar Spinal Stenosis | Device: CONDUIT™ Interbody Platform composed of the EIT (Emerging Implant Technologies) Cellular Titanium® | Farhan Karim | DePuy Synthes | Not yet recruiting | 35 Years | 80 Years | All | 150 | United States |